Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Best corrected visual acuity
研究概览
简要总结
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
详细描述
Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 58 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Significant epiretinal membrane
- •Anti-VEGF treatment for age-related macular degeneration
排除标准
- •Macular disorders
- •Diabetic retinopathy
- •Vascular occlusions
结局指标
主要结局
Best corrected visual acuity
时间窗: 12 months
Evaluate the best visual acuity during the follow up.
Central macular thickness
时间窗: 12 months
Evaluation of the retinal thickness changes with anti-VEGF treatment
Fluorescein angiogram
时间窗: 12 months
Evaluation of changes in lesion size during follow-up.
次要结局
未报告次要终点
研究者
Peter E. Liggett
Principal Investigator
New England Retina Associates